Olmos, L C
Sayed, M S
Moraczewski, A L
Gedde, S J
Rosenfeld, P J
Shi, W
Feuer, W J
Lee, R K
Article History
Received: 7 June 2015
Accepted: 28 October 2015
First Online: 18 December 2015
Competing interests
: PJR received research support from Acucela, Apellis, Genentech/Roche, GlaxoSmithKline, Neurotech, Ocata Therapeutics, and Tyrogenex. He is a consultant for Achillion, Acucela, Alcon, Bayer, Chengdu Kanghong Biotech, CoDa Therapeutics, Genentech/Roche, Healios K.K., Merck, Regeneron, Stealth and Tyrogenex. LCO is on the Scientific Advisory Board for: Alcon surgical, ScienceBased Health (none of them relevant to the published work). The other authors have no financial interests in any of the products discussed in this article. The Bascom Palmer Eye Institute is supported by NIH Center Core Grant P30EY014801 and a Research to Prevent Blindness Unrestricted Grant. Author contributions RKL, LCO, ALM, MSS, PJR and SJG participated in the conception and design of this study, analysis, and interpretation of data. WS and WJF participated in the statistical analysis and interpretation of the data. RKL, LCO, and MSS participated in drafting the article and revising it critically for important intellectual content and final approval of the version to be published. Ethics approval was provided by the University of Miami Miller School of Medicine Institutional Review Board.